TY - JOUR
T1 - Rodent models of TDP-43 proteinopathy
T2 - Investigating the mechanisms of TDP-43-mediated neurodegeneration
AU - Gendron, Tania F.
AU - Petrucelli, Leonard
N1 - Funding Information:
Acknowledgments This work was supported by Mayo Clinic Foundation (LP), National Institutes of Health/National Institute on Aging [R01AG026251 (LP)], National Institutes of Health/National Institute of Neurological Disorders and Stroke [R01 NS 063964–01 (LP), R21 NS074121-01 (TFG)], Amyotrophic Lateral Sclerosis Association (LP and TFG), and the Department of Defense [W81XWH-10-1-0512-1 and W81XWH-09-1-0315 (LP)].
PY - 2011/11
Y1 - 2011/11
N2 - Since the identification of phosphorylated and truncated transactive response DNA-binding protein 43 (TDP-43) as a primary component of ubiquitinated inclusions in amyotrophic lateral sclerosis and frontotemporal lobar degeneration with ubiquitin-positive inclusions, much effort has been directed towards ascertaining how TDP-43 contributes to the pathogenesis of disease. As with other protein misfolding disorders, TDP-43-mediated neuronal death is likely caused by both a toxic gain and loss of TDP-43 function. Indeed, the presence of cytoplasmic TDP-43 inclusions is associated with loss of nuclear TDP-43. Moreover, post-translational modifications of TDP-43, including phosphorylation, ubiquitination, and cleavage into C-terminal fragments, may bestow toxic properties upon TDP-43 and cause TDP-43 dysfunction. However, the exact neurotoxic TDP-43 species remain unclear, as do the mechanism(s) by which they cause neurotoxicity. Additionally, given our incomplete understanding of the roles of TDP-43, both in the nucleus and the cytoplasm, it is difficult to truly appreciate the detrimental consequences of aberrant TDP-43 function. The development of TDP-43 transgenic animal models is expected to narrow these gaps in our knowledge. The aim of this review is to highlight the key findings emerging from TDP-43 transgenic animal models and the insight they provide into the mechanisms driving TDP-43-mediated neurodegeneration.
AB - Since the identification of phosphorylated and truncated transactive response DNA-binding protein 43 (TDP-43) as a primary component of ubiquitinated inclusions in amyotrophic lateral sclerosis and frontotemporal lobar degeneration with ubiquitin-positive inclusions, much effort has been directed towards ascertaining how TDP-43 contributes to the pathogenesis of disease. As with other protein misfolding disorders, TDP-43-mediated neuronal death is likely caused by both a toxic gain and loss of TDP-43 function. Indeed, the presence of cytoplasmic TDP-43 inclusions is associated with loss of nuclear TDP-43. Moreover, post-translational modifications of TDP-43, including phosphorylation, ubiquitination, and cleavage into C-terminal fragments, may bestow toxic properties upon TDP-43 and cause TDP-43 dysfunction. However, the exact neurotoxic TDP-43 species remain unclear, as do the mechanism(s) by which they cause neurotoxicity. Additionally, given our incomplete understanding of the roles of TDP-43, both in the nucleus and the cytoplasm, it is difficult to truly appreciate the detrimental consequences of aberrant TDP-43 function. The development of TDP-43 transgenic animal models is expected to narrow these gaps in our knowledge. The aim of this review is to highlight the key findings emerging from TDP-43 transgenic animal models and the insight they provide into the mechanisms driving TDP-43-mediated neurodegeneration.
KW - Amyotrophic lateral sclerosis
KW - Frontotemporal lobar degeneration
KW - Neurodegeneration
KW - TDP-43
KW - Transgenic animal models
UR - http://www.scopus.com/inward/record.url?scp=80855138138&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80855138138&partnerID=8YFLogxK
U2 - 10.1007/s12031-011-9610-7
DO - 10.1007/s12031-011-9610-7
M3 - Article
C2 - 21811811
AN - SCOPUS:80855138138
SN - 0895-8696
VL - 45
SP - 486
EP - 499
JO - Molecular and Chemical Neuropathology
JF - Molecular and Chemical Neuropathology
IS - 3
ER -